VolitionRx’s NuQ® Assays Demonstrate 80% Detection Rate in Prostate Cancer

News   Mar 17, 2014

 
VolitionRx’s NuQ® Assays Demonstrate 80% Detection Rate in Prostate Cancer
 
 
 
 

RELATED ARTICLES

Acquisition Sees Agilent Gain Powerful NGS IP Portfolio

News

Agilent Technologies announces its acquisition of the molecular and sample barcoding portfolios of Population Genetics Technologies.

READ MORE

Protein Discovery Could Lead to Better Diagnosis of Stress

News

Researchers have found a protein that is present in people while they are in stressful situations. The discovery could lead to identifying new ways to predict, diagnose and treat stress.

READ MORE

Researchers Develop New Method to Generate Human Antibodies

News

Researchers hope their approach will help researchers rapidly generate therapeutic antibodies for the treatment of infectious diseases and other conditions such as cancer.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Biopharma Cancer Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE